다발성 골수종 시장 : 세계 규모, 점유율, 동향 분석, 기회, 예측 리포트(2019-2029년)

Multiple Myeloma Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Treatment ; By Diagnosis ; By Region

US $ 4,850 ￦ 6,630,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,750 ￦ 7,860,000

Unprintable PDF (Group License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,141,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. Excel 파일이 제공됩니다.

한글목차

세계의 다발성 골수종 시장 규모는 안정된 CAGR 5.39%로 성장하며, 2029년까지 294억 달러에 도달

세계 다발성골수종 시장은 세계에서 다발성골수종 치료 및 관리에 대한 관심이 증가하고 표적치료제의 빠른 발전으로 인해 급성장하고 있습니다.

전략 컨설팅 및 시장 조사 전문 기업 BlueWeave Consulting은 최근 발표한 보고서에서 2022년 다발성 골수종 세계 시장 규모를 214억 6,000만 달러로 추정했습니다. 다발성 골수종 시장 규모는 연평균 5.39%의 괄목할 만한 성장세를 보이며 2029년에는 294억 달러에 달할 것으로 예측했습니다. 세계 다발성 골수종 시장의 주요 성장 촉진요인으로는 마이크로 RNA 치료법의 채택 확대가 꼽힙니다. 이러한 혁신적인 치료법은 유전자 발현을 조절하고 다양한 세포 과정을 감독하는 마이크로 RNA의 잠재력을 활용합니다. 정밀하게 표적화된 마이크로 RNA 치료법의 발전은 다발성 골수종에 대해 보다 개인화되고 정확한 치료법을 제공할 것으로 기대됩니다. 또한 첨단 생물의학 플랫폼의 등장은 다발성골수종 시장 확대를 촉진하는 데 있으며, 매우 중요한 역할을 하고 있습니다. 이러한 다면적인 플랫폼은 질병의 분자적 기초를 이해하고, 새로운 치료 표적을 발굴하며, 보다 효과적인 치료 접근법을 개발하는 데 도움이 되는 다양한 기술과 방법론을 포함하고 있습니다. 이러한 정교한 플랫폼의 역량을 통해 연구자와 의료 전문가들은 다발성골수종의 복잡성을 더 깊이 파고들어 획기적인 치료법을 개발할 수 있습니다. 그러나 높은 치료 비용과 엄격한 규제 요건은 예측 기간 중 전체 시장 성장을 억제할 것으로 예상됩니다.

이 보고서는 세계 다발성 골수종 시장의 성장 잠재력, 향후 동향 및 통계에 대한 정보를 제공합니다. 또한 전체 시장 규모 예측을 촉진하는 요인을 파악할 수 있습니다. 이 보고서는 세계 다발성 골수종 시장의 최근 기술 동향과 의사결정자가 건전한 전략적 의사결정을 내릴 수 있는 업계 인사이트를 제공하기 위해 노력하고 있습니다. 또한 시장의 성장 촉진요인, 과제, 경쟁력에 대해도 분석합니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 다발성 골수종 시장에 관한 인사이트

• 업계의 밸류체인 분석
• DROC 분석
  • 성장 촉진요인
    • 전 세계에서 다발성 골수종의 발생률이 증가
    • 분자 표적약의 진보
  • 억제요인
    • 고액의 치료비
    • 엄격한 규제 요건
  • 기회
    • 신흥 시장
    • 맞춤형 의료
  • 과제
    • 경쟁
    • 약제 내성
• 기술의 진보/최근 개발
• 규제 프레임워크
• Porter's Five Forces 분석

제4장 세계의 다발성 골수종 시장 개요

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
    • Smoldering(indolent) 다발성 골수종
    • 활동성(증후성) 다발성 골수종
  • 치료별
    • 화학요법
    • 표적치료
    • 면역조절제
    • 스테로이드
    • Bone-modifying Drugs
    • 면역치료
    • 골수/줄기세포 이식
    • 방사선 치료
    • 수술
    • 기타
  • 진단별
    • 혈액검사와 요검사
    • X선
    • 자기공명영상 법(MRI)
    • 컴퓨터단층촬영(CT 또는 CAT) 스캔
    • 양전자 방사 단층촬영법(PET) 또는 PET-CT 스캔
    • 골수천자와 생검
    • 지방체 흡인
    • 종양 바이오마커 검사
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양(APAC)
    • 라틴아메리카(LATAM)
    • 중동 및 아프리카(MEA)

제5장 북미 다발성 골수종 시장

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 진단별
  • 국가별
    • 미국
    • 캐나다

제6장 유럽 다발성 골수종 시장

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 진단별
  • 국가별
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인
    • 벨기에
    • 러시아
    • 네덜란드
    • 기타 유럽

제7장 아시아태평양의 다발성 골수종 시장

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 진단별
  • 국가별
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주와 뉴질랜드
    • 인도네시아
    • 말레이시아
    • 싱가포르
    • 베트남
    • APAC 기타 국가

제8장 라틴아메리카의 다발성 골수종 시장

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 진단별
  • 국가별
    • 브라질
    • 멕시코
    • 아르헨티나
    • 페루
    • 중남미의 기타 지역

제9장 중동 및 아프리카의 다발성 골수종 시장

• 시장 규모와 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 진단별
  • 국가별
    • 사우디아라비아
    • 아랍에미리트
    • 카타르
    • 쿠웨이트
    • 남아프리카공화국
    • 나이지리아
    • 알제리
    • MEA의 나머지 부분

제10장 경쟁 구도

• 주요 기업과 제품 리스트
• 다발성 골수종 세계 시장 점유율 분석, 2022년
• 경영 파라미터에 의한 경쟁 벤치마킹
• 주요 전략적 개발(합병, 인수, 파트너십 등)

제11장 세계의 다발성 골수종 시장에 대한 COVID-19의 영향

12 : 기업 개요(회사 개요, 재무 매트릭스, 경쟁 구도, 주요 인재, 주요 경쟁, 연락처 주소, 전략적 전망, SWOT 분석)

• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck &Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd
• ONO Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Company Ltd
• Roche Group
• 기타 주요 기업

제13장 주요 전략적 권장사항

제14장 조사 방법

KSA

영문 목차

영문목차

Global Multiple Myeloma Market Size Grows at Steady CAGR of 5.39% to Reach USD 29.4 Billion by 2029.

Global multiple myeloma market is flourishing because of the growing focus on the treatment and management of increasing incidences of multiple myeloma globally and rapid advancements in targeted drugs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global multiple myeloma market size at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global multiple myeloma market size to grow at a significant CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include the increasing adoption of microRNA therapies. These innovative treatment modalities harness the potential of microRNAs to regulate gene expression and oversee diverse cellular processes. The evolution of precisely targeted microRNA therapies holds promise for delivering more individualized and accurate treatments for multiple myeloma. Furthermore, the ascent of advanced biomedicine platforms plays a pivotal role in propelling the expansion of the multiple myeloma market. These multifaceted platforms encompass a wide spectrum of technologies and methodologies that facilitate the understanding of the molecular foundations of the disease, the identification of novel therapeutic targets, and the development of more effective treatment approaches. By harnessing the capabilities of these sophisticated platforms, researchers and healthcare professionals can delve deeper into the intricacies of multiple myeloma, thereby advancing the creation of groundbreaking therapeutic interventions. However, high treatment costs and stringent regulatory requirements are anticipated to restrain the overall market growth during the forecast period.

Global Multiple Myeloma Market - Overview:

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The Global Multiple Myeloma Market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market - By Treatment

Based on treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery segments. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs, such as Thalomid, Revlimid, and pomalyst, being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Competitive Landscape:

Major players operating in the global multiple myeloma market include: Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Multiple Myeloma Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Multiple Myeloma Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Multiple Myeloma Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. The rising incidence of Multiple Myeloma globally
    • 3.2.1.2. Advancements in targeted drugs
  • 3.2.2. Restraints
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Stringent regulatory requirements
  • 3.2.3. Opportunities
    • 3.2.3.1. Emerging markets
    • 3.2.3.2. Personalized medicine
  • 3.2.4. Challenges
    • 3.2.4.1. Competition
    • 3.2.4.2. Drug resistance
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Multiple Myeloma Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Smoldering (indolent) Multiple Myeloma
    • 4.2.1.2. Active (symptomatic) Multiple Myeloma
  • 4.2.2. By Treatment
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Targeted Therapy
    • 4.2.2.3. Immunomodulatory Drugs
    • 4.2.2.4. Steroids
    • 4.2.2.5. Bone-modifying Drugs
    • 4.2.2.6. Immunotherapy
    • 4.2.2.7. Bone Marrow/Stem Cell Transplantation
    • 4.2.2.8. Radiation Therapy
    • 4.2.2.9. Surgery
    • 4.2.2.10. Others
  • 4.2.3. By Diagnosis
    • 4.2.3.1. Blood & Urine Tests
    • 4.2.3.2. X-ray
    • 4.2.3.3. Magnetic Resonance Imaging (MRI)
    • 4.2.3.4. Computed Tomography (CT or CAT) Scan
    • 4.2.3.5. Positron Emission Tomography (PET) or PET-CT Scan
    • 4.2.3.6. Bone Marrow Aspiration and Biopsy
    • 4.2.3.7. Fat Pad Aspirate
    • 4.2.3.8. Biomarker Testing of the Tumor
    • 4.2.3.9. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Multiple Myeloma Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By Diagnosis
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Type
    • 5.2.4.1.2. By Treatment
    • 5.2.4.1.3. By Diagnosis
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Type
    • 5.2.4.2.2. By Treatment
    • 5.2.4.2.3. By Diagnosis

6. Europe Multiple Myeloma Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Type
    • 6.2.4.1.2. By Treatment
    • 6.2.4.1.3. By Diagnosis
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Type
    • 6.2.4.2.2. By Treatment
    • 6.2.4.2.3. By Diagnosis
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Type
    • 6.2.4.3.2. By Treatment
    • 6.2.4.3.3. By Diagnosis
    • 6.2.4.4. France
    • 6.2.4.4.1. By Type
    • 6.2.4.4.2. By Treatment
    • 6.2.4.4.3. By Diagnosis
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Type
    • 6.2.4.5.2. By Treatment
    • 6.2.4.5.3. By Diagnosis
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Type
    • 6.2.4.6.2. By Treatment
    • 6.2.4.6.3. By Diagnosis
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Type
    • 6.2.4.7.2. By Treatment
    • 6.2.4.7.3. By Diagnosis
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Type
    • 6.2.4.8.2. By Treatment
    • 6.2.4.8.3. By Diagnosis
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Type
    • 6.2.4.9.2. By Treatment
    • 6.2.4.9.3. By Diagnosis

7. Asia-Pacific Multiple Myeloma Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Type
    • 7.2.4.1.2. By Treatment
    • 7.2.4.1.3. By Diagnosis
    • 7.2.4.2. India
    • 7.2.4.2.1. By Type
    • 7.2.4.2.2. By Treatment
    • 7.2.4.2.3. By Diagnosis
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Type
    • 7.2.4.3.2. By Treatment
    • 7.2.4.3.3. By Diagnosis
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Type
    • 7.2.4.4.2. By Treatment
    • 7.2.4.4.3. By Diagnosis
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Type
    • 7.2.4.5.2. By Treatment
    • 7.2.4.5.3. By Diagnosis
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Type
    • 7.2.4.6.2. By Treatment
    • 7.2.4.6.3. By Diagnosis
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Type
    • 7.2.4.7.2. By Treatment
    • 7.2.4.7.3. By Diagnosis
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Type
    • 7.2.4.8.2. By Treatment
    • 7.2.4.8.3. By Diagnosis
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Type
    • 7.2.4.9.2. By Treatment
    • 7.2.4.9.3. By Diagnosis
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Type
    • 7.2.4.10.2. By Treatment
    • 7.2.4.10.3. By Diagnosis

8. Latin America Multiple Myeloma Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Treatment
    • 8.2.4.1.3. By Diagnosis
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Treatment
    • 8.2.4.2.3. By Diagnosis
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Type
    • 8.2.4.3.2. By Treatment
    • 8.2.4.3.3. By Diagnosis
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Type
    • 8.2.4.4.2. By Treatment
    • 8.2.4.4.3. By Diagnosis
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Type
    • 8.2.4.5.2. By Treatment
    • 8.2.4.5.3. By Diagnosis

9. Middle East & Africa Multiple Myeloma Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Treatment
    • 9.2.4.1.3. By Diagnosis
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Treatment
    • 9.2.4.2.3. By Diagnosis
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Treatment
    • 9.2.4.3.3. By Diagnosis
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Treatment
    • 9.2.4.4.3. By Diagnosis
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Treatment
    • 9.2.4.5.3. By Diagnosis
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Treatment
    • 9.2.4.6.3. By Diagnosis
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Treatment
    • 9.2.4.7.3. By Diagnosis
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Treatment
    • 9.2.4.8.3. By Diagnosis

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Multiple Myeloma Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Multiple Myeloma Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Sanofi
• 12.2. Pfizer Inc.
• 12.3. GlaxoSmithKline plc
• 12.4. Novartis AG
• 12.5. Bayer AG
• 12.6. Eli Lilly and Company
• 12.7. Merck & Co., Inc.
• 12.8. AstraZeneca
• 12.9. Bristol-Myers Squibb Company
• 12.10. AbbVie Inc.
• 12.11. Teva Pharmaceutical Industries Ltd
• 12.12. ONO Pharmaceutical Co., Ltd
• 12.13. Takeda Pharmaceutical Company Ltd
• 12.14. Roche Group
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations

관련자료